Is Pfizer Inc. (PFE) One of Goldman Sachs Top Healthcare Stocks?

Piotr Kowalski/Shutterstock.com

Trial results showed that the once-a-month inhibitor achieved a placebo-adjusted precocious of 51.9% successful the middle-dose group. It compares to a precocious of 36% astatine 16 weeks for Regeneron’s Dupixent. The investigational cause besides met its superior endpoint successful the Phase 2 survey for adults with atopic dermatitis, a tegument illness that causes itching.

The proceedings results suggest a perchance higher competitory profile, with greater efficacy than the existent attraction enactment from Sanofi and Regeneron. The affirmative results fortify the company’s positioning successful the immunology and inflammation sectors. In addition, it should supply Pfizer with a catalyst arsenic it continues to rebuild momentum crossed its pipeline.

Pfizer Inc. (NYSE:PFE) is simply a starring planetary biopharmaceutical institution that discovers, develops, manufactures, and markets innovative medicines and vaccines to dainty and forestall diseases. Focused connected oncology, inflammation, immunology, and vaccines, Pfizer offers implicit 150 products worldwide, including large COVID-19 vaccines and treatments.

While we admit the imaginable of PFE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Affordable Growth Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey connected Google News.